Table III.
Mean values and standrd deviation (SD) of OPN and MMP-9 levels, and MMP-9 activity in 53 controls and 18 melanoma cases at diagnosis and at 3 months post-surgery.
| Time of markes evaluation (mean ± SD) | |||
|---|---|---|---|
| Marker | No. | At enrolment | At 3 months post-surgery |
| OPN | |||
| Controls | 53 | 42.3 (25.3) | |
| Melanoma, SL Neg | 4 | 189.0 (14.6) | 34.3 (14.5) |
| Melanoma, SL Pos | 14 | 208.1 (25.5) | 45.6 (15.8) |
| MMP-9 | |||
| Controls | 53 | 36.6 (14.2) | |
| Melanoma, SL Neg | 4 | 162.6 (31.3) | 30.0 (9.0) |
| Melanoma, SL Pos | 14 | 186.6 (17.7) | 31.4 (10.9) |
| MMP-9 activity | |||
| Controls | 53 | 1.18 (0.69) | |
| Melanoma, SL Neg | 4 | 3.52 (1.32) | 1.14 (0.48) |
| Melanoma, SL Pos | 14 | 5.65 (1.33) | 1.40 (0.57) |
SL, sentinel lymphnode; OPN, osteopontin; MMP-9, matrix metalloproteinase-9; SL Neg, sentinel lymph node negative; SL Pos, sentinel lymph node positive.